And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

Anton Gueth Biography and Net Worth

Director of Antares Pharma

Mr. Anton G. Gueth is an Independent Director at Elevar Therapeutics, Inc., a Joint Managing Director at Evolution Life Science Partners, an Independent Director at Antares Pharma, Inc. and a President & Managing Partner at Gueth Consulting LLC. He is on the Board of Directors at Elevar Therapeutics, Inc. and Antares Pharma, Inc. Mr. Gueth was previously employed as a Chairman by Navidea Biopharmaceuticals, Inc., an Independent Director by Spectrum Pharmaceuticals, Inc., a Director-Northern California Chapter by American Liver Foundation, a Managing Director by Burrill Securities LLC, a Director-Alliance Management by Eli Lilly & Co., a Managing Director-Gulf & Yemen Operations by Eli Lilly Saudi Arabia Ltd., a Vice President-Business Development by NewBridge Pharmaceuticals FZ LLC, and a Vice President-Financial Planning & Treasury by PCS Health Systems, Inc. He also served on the board at Eqinox Healthcare France SASU and iQone Healthcare Holding. He received his graduate degree from Indiana University and a graduate degree from the University of Giessen.

What is Anton Gueth's net worth?: The estimated net worth of Anton Gueth is at least $2.61 million as of July 8th, 2021. Mr. Gueth owns 467,577 shares of Antares Pharma stock worth more than $2,613,755 as of April 20th. This net worth approximation does not reflect any other assets that Mr. Gueth may own. Learn More about Anton Gueth's net worth.
How do I contact Anton Gueth?: The corporate mailing address for Mr. Gueth and other Antares Pharma executives is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. Antares Pharma can also be reached via phone at (609) 359-3020 and via email at [email protected]. Learn More on Anton Gueth's contact information.
Has Anton Gueth been buying or selling shares of Antares Pharma?: Anton Gueth has not been actively trading shares of Antares Pharma within the last three months. Most recently, Anton Gueth sold 100,000 shares of the business's stock in a transaction on Thursday, July 8th. The shares were sold at an average price of $4.29, for a transaction totalling $429,000.00. Following the completion of the sale, the director now directly owns 467,577 shares of the company's stock, valued at $2,005,905.33. Learn More on Anton Gueth's trading history.
Who are Antares Pharma's active insiders?: Antares Pharma's insider roster includes Thomas Garrity (Director), and Anton Gueth (Director). Learn More on Antares Pharma's active insiders.

Anton Gueth Insider Trading History at Antares Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2021	Sell	100,000	$4.29	$429,000.00	467,577
9/3/2013	Sell	25,000	$4.42	$110,500.00	245,976
8/1/2013	Sell	25,000	$4.41	$110,250.00
7/1/2013	Sell	25,000	$4.15	$103,750.00
6/3/2013	Sell	25,000	$4.01	$100,250.00

Anton Gueth Buying and Selling Activity at Antares Pharma

Antares Pharma Company Overview

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Today's Range

Now: $5.59

$5.59

50 Day Range

MA: $5.59

$5.59

2 Week Range

Now: $5.59

$3.11

$5.60

Volume

6 shs

Average Volume

3,291,313 shs

Market Capitalization

$955.06 million

P/E Ratio

23.29

Dividend Yield

N/A

Beta

1.15

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here